These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37254731)

  • 1. Foundations of hemophilia and epidemiology.
    Quintana Paris L
    Blood Coagul Fibrinolysis; 2023 Jun; 34(S1):S35-S36. PubMed ID: 37254731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of hemophilia in developing countries.
    Kashyap R; Choudhry VP
    Indian J Pediatr; 2001 Feb; 68(2):151-7. PubMed ID: 11284184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive care for hemophilia and other inherited bleeding disorders.
    Page D
    Transfus Apher Sci; 2019 Oct; 58(5):565-568. PubMed ID: 31427262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of pharmacokinetics in the management of hemophilia.
    Barnes C
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S27-9. PubMed ID: 23109436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolution of recombinant factor replacement for hemophilia.
    Sankar AD; Weyand AC; Pipe SW
    Transfus Apher Sci; 2019 Oct; 58(5):596-600. PubMed ID: 31421983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia.
    McMillan CW; Greene WB; Blatt PM; White GC; Roberts HR
    Instr Course Lect; 1983; 32():210-6. PubMed ID: 6443730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The More Recent History of Hemophilia Treatment.
    Franchini M; Mannucci PM
    Semin Thromb Hemost; 2022 Nov; 48(8):904-910. PubMed ID: 36108649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemophilia A and B.
    Shearin-Patterson T; Davidson EJ
    JAAPA; 2013 Apr; 26(4):49. PubMed ID: 23610840
    [No Abstract]   [Full Text] [Related]  

  • 10. Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.
    Goldstein B; Geldziler B; Bjerre J; Seremetis S
    Transfus Apher Sci; 2008 Feb; 38(1):25-32. PubMed ID: 18267372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic properties and safety of recombinant factor VIII and factor IX.
    Zdziarska J; Chojnowski K; Klukowska A; Łetowska M; Mital A; Podolak-Dawidziak M; Windyga J; Zawilska K;
    Pol Arch Med Wewn; 2009 Jun; 119(6):403-9. PubMed ID: 19694223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy for hemophilia: looking beyond factor expression.
    Yamaguti-Hayakawa GG; Ozelo MC
    Exp Biol Med (Maywood); 2022 Dec; 247(24):2223-2232. PubMed ID: 36691324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemophilia and prophylaxis.
    Ljung R
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S23-6. PubMed ID: 23109472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemophilia in Iran.
    Dorgalaleh A; Dadashizadeh G; Bamedi T
    Hematology; 2016 Jun; 21(5):300-10. PubMed ID: 26914731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
    Mahasandana C; Patharathienskul D; Suvatte V
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substitution treatment of hemophilia a and b.
    Duckert F
    Schweiz Med Wochenschr; 1975 Jun; 105(24):783-4. PubMed ID: 1145162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the treatment of patients with factor IX deficiency to that of those with factor VIII deficiency: results of an International Survey conducted as part of the International FIX Treatment Network.
    Berntorp E; Shapiro AD; Waters J; Astermark J
    Haemophilia; 2014 Sep; 20(5):e362-4. PubMed ID: 25156443
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The management of hemophilia patients with inhibitors.
    Nilsson IM
    Transfus Med Rev; 1992 Oct; 6(4):285-93. PubMed ID: 1421831
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevention of bleeding in hemophilia patients with high-titer inhibitors.
    Leissinger CA; Konkle BA; Antunes SV
    Expert Rev Hematol; 2015 Jun; 8(3):375-82. PubMed ID: 25937074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.